Navigation Links
Phase 3 Results Show Canagliflozin as Add-On Therapy to Metformin and Pioglitazone Significantly Lowers Blood Sugar Levels in Adult Patients with Type 2 Diabetes
Date:11/9/2012

BARCELONA, Spain, Nov. 9, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced that its investigational medicine canagliflozin substantially lowered blood glucose levels compared to placebo when used as add-on therapy in patients with type 2 diabetes who are inadequately controlled with the antihyperglycemic medications metformin and pioglitazone. These results were presented at the 4th World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy). 

The data presented are the latest Phase 3 results for canagliflozin, which is being evaluated across a spectrum of patients with type 2 diabetes. Results from the study (known as DIA3012) showed that canagliflozin, dosed once daily at 100 mg or 300 mg in addition to metformin and pioglitazone, had statistically greater A1C reductions at 26 weeks relative to placebo (change from baseline, -0.89% and -1.03%, vs. -0.26%, respectively, p<0.001). The overall incidence of adverse events (AEs) was generally similar across all treatment arms.

"Given the global diabetes epidemic and the significant burden faced by patients who suffer from uncontrolled diabetes, it is critical that we evaluate new therapies in combination with existing antihyperglycemic therapies," said Dr. Thomas Forst, lead investigator on the study from the University of Mainz in Mainz, Germany. "The efficacy and safety profile for canagliflozin in this trial is encouraging. This data combined with other results seen to date, show that canagliflozin may provide added benefit in managing important diabetes parameters when used alone or in addition to existing diabetes treatments."

In secondary efficacy endpoint measures of the study, both the canagliflozin 100 mg and 300 mg dose groups provided reductions in body weight compared to placebo (-2.8% and -3.8% vs. -0.1%, respectively, p<0.001) and reductions in systolic blood pressure (-5.3 mmHg, p<0.01 and -4
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... ORLANDO, Fla. and DUBLIN , ... of the agreement with KRS Global Biotechnology, Inc. for the ... will be compounded for shipment in the United ... 503B FDA approved Outsourcing Facility capable of compounding naltrexone tablets ...
(Date:1/23/2015)... available for sale, The Armor1 Ankle Roll Guard is a ... by cushioning the ankle from an inversion or "roll." ... of any shoe type and allows the user to ... against sprains. With customers in physical therapy, podiatry, and ...
(Date:1/23/2015)... 23, 2015   Leatt Corporation  (OTCQB: LEAT), a global ... all forms of sports, including extreme motor sports, and ... today that the UISP Lega Motociclismo Lombardia, an Italian ... to wear a neck brace during its racing competitions.  ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3
... Jan. 11, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: ... trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor ... "PARP inihibtors have been validated to show survival benefits ... repair or in combination with DNA damaging agents, and BMN ...
... Wis., Jan. 11, 2011 RF Technologies®, a ... and healthcare security solutions, has announced a distributor ... leading provider of medical equipment management and service ... on November 1, UHS will offer the RF ...
Cached Medicine Technology:BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 2BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 3RF Technologies® Announces Distributor Agreement With Universal Hospital Services 2
(Date:1/22/2015)... 2015 Woodloch Pines, an all-inclusive family ... by TripAdvisor as the number one best large hotel for ... the world for their annual Travelers’ Choice Awards. , ... The website is home to millions of unbiased and honest ...
(Date:1/22/2015)... 2015 Padre Murphy's and Owner Tom Boyle ... Pro Player Health Alliance (PPHA). The PPHA's passion for ... everyone, including NFL greats, treated for obstructive sleep apnea (OSA) ... supporting the cause in the valley. The most recent plans ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together by ... up to 30lbs in less than 12 weeks without traditional ... prompting an investigative review. , “Our Incredible Bulk review ... that allows the body to pack on a massive amount ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) wants ... “Live Fearless.” , The “Faces of Fearless” campaign ... how they or someone they know has faced a challenge, ... moment. By telling these types of stories through livefearlessmn.com, participants ...
(Date:1/22/2015)... The federal court overseeing thousands of vaginal ... Southern District of West Virginia has upheld a $2 million ... bellwether trial. In an Order dated January 21st, the Court ... that C.R. Bard had not proven a miscarriage of justice. ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4
... reports from government health officials and the World Health Organization, ... She is the virus’ first human victim, in a year ... Mon Puthy, had been in close proximity with sick and ... 40 miles west of Phnom Penh. According to WHO spokeswoman ...
... resonance imaging (MRI) has been found to be insufficient, ... ,MRI has been adopted in England and Wales ... (NICE) as part of the recommended criteria for diagnosing ... evidence has not previously been systematically assessed. ...
... Organization (WHO) and UNICEF have announced a new formula ... is designed to minimize the occurrence of acute diarrhoeal ... agencies achieve the target of reducing child mortality by ... cause of child mortality and kills nearly 2 million ...
... caused by hereditary predisposition. Atopy is a determining factor ... allergens may help prevent adults from developing asthma.//,Journal of ... atopy and specific IgE to mites and molds important ... conducted by Maritta S. Jaakkola, MD, DSc, of the ...
... Minister of Bihar Mr. Nitish Kumar is all for a ... used to cultivate potato, tomato and green vegetables// at their ... resource centre for herbal farming. ,Nitish Kumar comes ... was a leading ayurvedic practitioner in his home district of ...
... With the announcement of the Food Standards Agency (FSA), that the ... day, and that the tinned foods// should clearly mention the amount ... issue has now picked up, with groups on either side. ... government of UK, has announced targets for reducing salt in a ...
Cached Medicine News:Health News:MRI Scan Insufficient For Diagnosing Multiple Sclerosis 2Health News:Salt & Its Intake Causes a Strong debate In UK 2
... Endoscopic CycloPhotocoagulation (ECP) is a surgical approach ... and visualized laser application. The ciliary body ... the surgeon, from the anterior or posterior ... The target tissues are easily and accurately ...
... of German Craftsmanship have produced ... the world. Ocutek® now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
... Centuries of German Craftsmanship have ... in the world. Ocutek® now ... Only holders of the coveted ... eight-year apprenticeship, are qualified to ...
... Centuries of German Craftsmanship have ... in the world. Ocutek® now ... Only holders of the coveted ... eight-year apprenticeship, are qualified to ...
Medicine Products: